• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医院类型、首次组织学确诊方法及化疗时间对晚期原发性卵巢癌患者预后的影响。

The prognostic influence of hospital type, method of first histological confirmation and time to chemotherapy in patients with advanced primary ovarian cancer.

作者信息

Starke Olivia, Wimberger Pauline, Klotz Daniel Martin

机构信息

Department of Gynecology and Obstetrics, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.

National Center for Tumor Diseases/University Cancer Center (NCT/UCC): German Cancer Research Center (DKFZ), Heidelberg, Germany, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany.

出版信息

Arch Gynecol Obstet. 2025 Jun;311(6):1627-1635. doi: 10.1007/s00404-024-07832-4. Epub 2024 Dec 16.

DOI:10.1007/s00404-024-07832-4
PMID:39680144
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12055883/
Abstract

PURPOSE

Ovarian cancer is the fifth most common cancer in women and the leading cause of death of all gynecological malignancies. Prognosis is determined by optimal surgical outcome (macroscopic complete resection) most commonly achieved in tertiary hospitals. We investigated whether tertiary versus non-tertiary hospital as the location of an initial diagnostic intervention for histological confirmation before cytoreductive surgery versus immediate primary debulking surgery impacts outcome in patients with advanced ovarian cancer.

METHODS

We analyzed 115 patients who underwent cytoreductive surgery at a German tertiary center: 60 patients underwent primary debulking surgery (PDS) and 55 patients had a diagnostic intervention for histological confirmation before debulking surgery (PHC).

RESULTS

Although there was no prognostic difference between the two subgroups, the median time to chemotherapy was longer in the PHC group (46 days) compared to the PDS group (26 days; p < 0.0001), equally seen comparing non-tertiary versus tertiary PHC groups (p: 0.0001), its impact confirmed in a multivariate analysis (PFS: HR: 1.03, 95%CI: 1.01-1.05, p: 0.007; OS: HR: 1.04, 95%CI: 1.02 -1.06, p: < 0.001) of the PHC group only. In total, 9/10 patients with port-site metastases after diagnostic laparoscopy were initially treated at non-tertiary hospitals, resulting in a lower PFS compared to patients without port-site metastases after laparoscopy (HR 0.21, 95%CI 0.06-0.733, p: 0.014).

CONCLUSIONS

In conclusion, patients with ovarian cancer undergoing treatment solely at a tertiary center have some clinical benefits and improved outcome, given the shorter time to chemotherapy and potential impact of port-site metastases. This supports centralization of oncological treatment.

摘要

目的

卵巢癌是女性中第五大常见癌症,也是所有妇科恶性肿瘤的主要死亡原因。预后取决于最佳手术结果(宏观完全切除),这在三级医院最常实现。我们研究了作为初始诊断干预地点的三级医院与非三级医院,在进行细胞减灭术之前进行组织学确认的诊断干预与立即进行初次肿瘤细胞减灭术相比,对晚期卵巢癌患者的预后是否有影响。

方法

我们分析了在德国一家三级中心接受细胞减灭术的115例患者:60例患者接受了初次肿瘤细胞减灭术(PDS),55例患者在减灭术前进行了组织学确认的诊断干预(PHC)。

结果

虽然两个亚组之间没有预后差异,但PHC组的化疗中位时间(46天)比PDS组(26天)更长(p < 0.0001),非三级与三级PHC组比较也同样如此(p:0.0001),其影响在仅对PHC组的多因素分析中得到证实(无进展生存期:风险比:1.03,95%置信区间:1.01 - 1.05,p:0.007;总生存期:风险比:1.04,95%置信区间:1.02 - 1.06,p:< 0.001)。总共,10例诊断性腹腔镜检查后出现切口转移的患者中有9例最初在非三级医院接受治疗,与腹腔镜检查后无切口转移的患者相比,其无进展生存期更低(风险比0.21,95%置信区间0.06 - 0.733,p:0.014)。

结论

总之,鉴于化疗时间较短以及切口转移的潜在影响,仅在三级中心接受治疗的卵巢癌患者有一些临床益处且预后改善。这支持肿瘤治疗的集中化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23f5/12055883/51b1bcd25127/404_2024_7832_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23f5/12055883/f4c582a7e098/404_2024_7832_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23f5/12055883/51b1bcd25127/404_2024_7832_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23f5/12055883/f4c582a7e098/404_2024_7832_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/23f5/12055883/51b1bcd25127/404_2024_7832_Fig2_HTML.jpg

相似文献

1
The prognostic influence of hospital type, method of first histological confirmation and time to chemotherapy in patients with advanced primary ovarian cancer.医院类型、首次组织学确诊方法及化疗时间对晚期原发性卵巢癌患者预后的影响。
Arch Gynecol Obstet. 2025 Jun;311(6):1627-1635. doi: 10.1007/s00404-024-07832-4. Epub 2024 Dec 16.
2
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
3
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.超根治性(广泛)手术与标准手术治疗晚期上皮性卵巢癌的初步细胞减灭术。
Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3.
4
Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.高级别晚期卵巢癌的初次肿瘤细胞减灭术与初次新辅助化疗:生存比较。
Radiol Oncol. 2018 Sep 11;52(3):307-319. doi: 10.2478/raon-2018-0030.
5
Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer.新辅助化疗在手术前与手术后化疗用于晚期卵巢上皮癌的初始治疗。
Cochrane Database Syst Rev. 2021 Jul 30;7(7):CD005343. doi: 10.1002/14651858.CD005343.pub6.
6
Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study.晚期卵巢癌的集中式初级护理可改善完全细胞减灭术及生存率——一项基于人群的队列研究。
Gynecol Oncol. 2016 Aug;142(2):211-6. doi: 10.1016/j.ygyno.2016.05.025. Epub 2016 Jun 11.
7
Optimal primary surgical treatment for advanced epithelial ovarian cancer.晚期上皮性卵巢癌的最佳初次手术治疗
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD007565. doi: 10.1002/14651858.CD007565.pub2.
8
Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy.间隔减瘤手术不值得等待:一项比较原发细胞减灭术与新辅助化疗的国家癌症数据库研究。
Int J Gynecol Cancer. 2020 Jun;30(6):845-852. doi: 10.1136/ijgc-2019-001124. Epub 2020 Apr 26.
9
Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study.腹腔镜检查预测晚期卵巢癌患者初次细胞减灭术疗效的研究(LapOvCa-trial):一项多中心随机对照研究。
BMC Cancer. 2012 Jan 20;12:31. doi: 10.1186/1471-2407-12-31.
10
[Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].[晚期卵巢癌患者新辅助化疗后行间隔减瘤手术的预后获益相关因素分析]
Zhonghua Fu Chan Ke Za Zhi. 2021 Jun 25;56(6):385-392. doi: 10.3760/cma.j.cn112141-20201207-00871.

引用本文的文献

1
Earlier is not always better: Optimal time to initiate adjuvant chemotherapy after surgery for ovarian cancer.更早并不总是更好:卵巢癌术后辅助化疗的最佳起始时间。
Arch Gynecol Obstet. 2025 Jul 11. doi: 10.1007/s00404-025-08095-3.

本文引用的文献

1
Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.在 III 期 PAOLA-1/ENGOT-ov25 试验中,根据新诊断的晚期卵巢癌患者的临床风险,维持奥拉帕利联合贝伐珠单抗的疗效。
Gynecol Oncol. 2022 Feb;164(2):254-264. doi: 10.1016/j.ygyno.2021.12.016. Epub 2021 Dec 22.
2
The Pathogenesis and Prevention of Port-Site Metastasis in Gynecologic Oncology.妇科肿瘤学中端口部位转移的发病机制与预防
Cancer Manag Res. 2020 Oct 6;12:9655-9663. doi: 10.2147/CMAR.S270881. eCollection 2020.
3
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
尼拉帕利治疗新诊断的晚期卵巢癌患者。
N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28.
4
Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.在晚期卵巢癌患者中,减瘤手术和辅助化疗之间的时间间隔与总生存期相关。
Gynecol Oncol. 2018 Sep;150(3):446-450. doi: 10.1016/j.ygyno.2018.07.004. Epub 2018 Jul 9.
5
Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.腹腔镜预测晚期卵巢癌患者初次细胞减灭术疗效的前瞻性随机对照研究。
J Clin Oncol. 2017 Feb 20;35(6):613-621. doi: 10.1200/JCO.2016.69.2962. Epub 2016 Dec 28.
6
Chemotherapy delay after primary debulking surgery for ovarian cancer.卵巢癌初次肿瘤细胞减灭术后的化疗延迟。
Gynecol Oncol. 2017 Feb;144(2):260-265. doi: 10.1016/j.ygyno.2016.11.022. Epub 2016 Nov 29.
7
Prognostic Impact of Port-Site Metastasis After Diagnostic Laparoscopy for Epithelial Ovarian Cancer.诊断性腹腔镜检查后上皮性卵巢癌端口部位转移的预后影响
Ann Surg Oncol. 2016 Dec;23(Suppl 5):834-840. doi: 10.1245/s10434-016-5415-9. Epub 2016 Jul 12.
8
Centralized primary care of advanced ovarian cancer improves complete cytoreduction and survival - A population-based cohort study.晚期卵巢癌的集中式初级护理可改善完全细胞减灭术及生存率——一项基于人群的队列研究。
Gynecol Oncol. 2016 Aug;142(2):211-6. doi: 10.1016/j.ygyno.2016.05.025. Epub 2016 Jun 11.
9
Unexpected gynecologic malignancy diagnosed after hysterectomy performed for benign indications.因良性指征行子宫切除术后诊断出意外的妇科恶性肿瘤。
Obstet Gynecol. 2015 Feb;125(2):397-405. doi: 10.1097/AOG.0000000000000642.
10
Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).FIGO 分期 IV 期卵巢癌患者中残余肿瘤对结局的影响:AGO-OVAR(妇科肿瘤学卵巢癌研究组)的探索性分析。
Ann Surg Oncol. 2010 Jun;17(6):1642-8. doi: 10.1245/s10434-010-0964-9. Epub 2010 Feb 18.